---
title: 'Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell
  lung cancer: a phase 2 umbrella trial'
date: '2024-02-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38351187/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240214170735&v=2.18.0
source: heidelberg[Affiliation]
description: For patients with non-small-cell lung cancer (NSCLC) tumors without currently
  targetable molecular alterations, standard-of-care treatment is immunotherapy with
  anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However,
  not all patients derive durable benefit and resistance to immune checkpoint blockade
  is common. Understanding mechanisms of resistance-which can include defects in DNA
  damage response and repair pathways, alterations or functional mutations ...
disable_comments: true
---
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common. Understanding mechanisms of resistance-which can include defects in DNA damage response and repair pathways, alterations or functional mutations ...